Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lisaftoclax (APG-2575) + Pd or DRd in R/R Multiple Myeloma and AL Amyloidosis
NCT04942067Phase 2Recruiting
- Sponsor
- Ascentage Pharma
- Start
- Dec 2021
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lisaftoclax in multiple myeloma (MM) and immunoglobulin light chain amyloidosis (3 arms), sponsored by Ascentage Pharma. Primary endpoint: Dose Limiting Toxicity at 28 days. Started Dec 2021; status: recruiting.
02
Drugs
lisaftoclax
03
Conditions
multiple myeloma (MM)immunoglobulin light chain amyloidosis
Beyond the preview
Go deeper on NCT04942067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04942067.